---
schema_version: "secwatch.filing_event.v1"
accession: "0000856982-25-000035"
form_type: "8-K"
ticker: "MMSI"
cik: "0000856982"
company_name: "MERIT MEDICAL SYSTEMS INC"
filed_at: "2025-05-20T23:59:59+00:00"
generated_at: "2026-05-21T00:52:28.053997+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Merit Medical acquires Biolife for $120M in cash; adds StatSeal/WoundSeal hemostasis products

## Summary
- Purchase price $120M cash; Biolife becomes wholly-owned subsidiary of Merit.
- Biolife's revenue projected at ~$18M annualized starting FY 2026 with mid-teens growth.
- StatSeal/WoundSeal products address ~$350M global hemostasis market.
- Merit reaffirms FY 2025 guidance; acquisition slightly dilutive to 2025 non-GAAP profitability.

## SEC filing metadata
- accession: 0000856982-25-000035
- form_type: 8-K
- ticker: MMSI
- cik: 0000856982
- company_name: MERIT MEDICAL SYSTEMS INC
- filed_at: 2025-05-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/856982/000085698225000035/0000856982-25-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/856982/000085698225000035/mmsi-20250516x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000856982-25-000035
- JSON: https://secwatch.observer/filing/0000856982-25-000035.json
- Plain text: https://secwatch.observer/filing/0000856982-25-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.